Quick Take
- Manipal Health targets Rs 80,000 Cr ($8.3 Bn) valuation, down from $10-12 Bn earlier
- Temasek-backed chain plans to raise up to Rs 11,000 Cr through the share sale
- Issue likely opens week of July 27, set to be India’s biggest listing of 2026
In This Article
Manipal Health Enterprises has cut its Manipal IPO valuation target to about Rs 80,000 Cr ($8.3 Bn), down from the $10-12 Bn range it marketed in April 2026, Bloomberg reported on July 17, 2026.
The Temasek-backed hospital operator plans to raise up to Rs 11,000 Cr through the share sale, which is likely to open in the week beginning July 27, 2026. The Bengaluru company runs the Manipal Hospitals chain and received its SEBI (Securities and Exchange Board of India) observation letter earlier in July.
StartupFeed Insight
The 20 to 30 percent haircut is not a verdict on Manipal’s business, it is a verdict on the size of the cheque. A Rs 11,000 Cr book needs domestic mutual funds and foreign institutions to write large tickets on the same day, and Middle East volatility has made both groups price risk harder. Founders planning listings above Rs 5,000 Cr should watch this closely, because anchor demand now sets the valuation, not the banker’s model. StartupFeed expects at least two more large Indian IPOs to reprice downward before September 30, 2026, with healthcare and consumer issues taking the sharpest cuts. By Avinash.
Manipal IPO Valuation: The Numbers Behind the Cut
The revised Manipal IPO valuation of Rs 80,000 Cr sits roughly Rs 20,000 Cr below the top end of the April marketing range. Bloomberg reported the figure on July 17, 2026, citing people familiar with the deliberations.
| Metric | Detail | Notes |
|---|---|---|
| Target Valuation | Rs 80,000 Cr ($8.3 Bn) | Down from $10-12 Bn, Bloomberg |
| Total Issue Size | Up to Rs 11,000 Cr ($1.14 Bn) | Fresh issue plus offer for sale |
| Fresh Issue | Rs 8,000 Cr | Per DRHP filed March 2026 |
| Offer For Sale | Up to 4.32 Cr shares | Temasek, TPG, Novo Holdings selling |
| Likely Open Date | Week of July 27, 2026 | Timing may still change |
| Pre-IPO Placement | Up to Rs 1,600 Cr | Would reduce fresh issue size |
The most striking number is the gap itself. Manipal marketed a $12 Bn story in April 2026 and is now testing investors at $8.3 Bn, a cut of roughly 30 percent at the top end within four months.
About Manipal Health Enterprises
Manipal Health Enterprises runs India’s largest hospital network by bed capacity under the Manipal Hospitals brand. Founded in 1953 by T. M. A. Pai and headquartered in Bengaluru, the company earns revenue from inpatient, outpatient and complex tertiary care. It operated 49 hospitals with 12,631 beds as of December 31, 2025, per its DRHP. Backers include Temasek, TPG Asia and Novo Holdings.
How does the Manipal IPO valuation compare to peers?
At Rs 80,000 Cr, Manipal would list below both Apollo Hospitals and Max Healthcare, each of which crossed Rs 1 lakh crore in market capitalisation during 2026. Manipal reported FY25 revenue of Rs 8,242.2 Cr and net profit of Rs 1,081.6 Cr, per its DRHP. Apollo posted FY25 revenue of Rs 21,794 Cr, though that figure includes pharmacy and diagnostics.
The targeted valuation reflects cautious investor sentiment toward large public offerings, as tensions in the Middle East spark turbulence in global financial markets, people familiar with the matter told Bloomberg.
Read on a pure hospital basis, the discount narrows considerably. Manipal’s Rs 8,242.2 Cr top line comes almost entirely from hospitals, which makes its revenue multiple closer to peers than headline market caps suggest. The question for anchor investors is whether Manipal can lift occupancy and ARPOB (Average Revenue Per Occupied Bed) across recently acquired assets fast enough to justify a premium rating.
How will Manipal use the IPO proceeds?
Manipal has earmarked Rs 5,378 Cr of fresh issue proceeds for repaying borrowings of material subsidiary Manipal Hospitals Private Limited, per the DRHP. Another Rs 574 Cr goes toward buying a minority stake in step-down subsidiary Sahyadri Hospitals, with the balance for general corporate purposes.
Debt repayment dominates the plan, which matters for margins. Lower interest costs feed directly into profit after tax, and the company has leaned on debt to fund five acquisitions since 2021: Columbia Asia, Vikram Hospital, AMRI Hospitals, Medica Synergie and Sahyadri. The Sahyadri deal alone, closed in October 2025, added 1,606 licensed beds.
Kotak Mahindra Capital, Axis Capital, Goldman Sachs India, Jefferies India, JP Morgan India, UBS Securities India and DBS Bank India are book-running lead managers. KFin Technologies is the registrar. Shares will list on both BSE and NSE.
Can Manipal beat Apollo and Max on the bourses?
Manipal enters a listed field where scale and efficiency pull in different directions. The company leads on beds but trails Max Healthcare on revenue per bed, which is the metric fund managers watch most closely in hospital stocks.
| Company | FY25 Revenue | Scale |
|---|---|---|
| Manipal Health | Rs 8,242.2 Cr | 49 hospitals, 12,631 beds |
| Apollo Hospitals | Rs 21,794 Cr | 73 hospitals, 8,000+ beds |
| Max Healthcare | Rs 7,028 Cr | 20 hospitals, 3,454 beds |
What sets Manipal apart is its acquisition engine. No Indian hospital group has folded five separate chains into one national platform in five years, and that integration record is the core of its listing pitch.
What’s Next
Watch the anchor book. Manipal is expected to open the issue in the week starting July 27, 2026, and the anchor allocation lands one working day before that. Deliberations on valuation, size and timing could still change, per Bloomberg. If domestic mutual funds take more than half the anchor portion, the Rs 80,000 Cr mark holds. Will retail investors follow institutions into India’s largest listing of 2026?
Frequently Asked Questions
Disclaimer: This article is for informational purposes only and does not constitute investment advice. StartupFeed and its authors are not SEBI-registered investment advisors. The analysis above is based on publicly available information and should not be the sole basis for any investment decision. Please consult a SEBI-registered financial advisor before making investment decisions.
Written by Avinash. Have a tip? Write to us at editorial@startupfeed.in.
